Abefolastat tesaroxetan CU-64 clinical trials
Its developmentBy Clarity Pharmaceuticals, step by step5 company-led studies, furthest phase 3: when each phase was reached, its deals, target and what is ahead.How each study uses abefolastat tesaroxetan CU-64 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the abefolastat tesaroxetan CU-64 studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Name
- 64Cu-SAR-bisPSMA
- 6
Studies by the year they started
6 studies that test it; most in 2021 (2)
| Year | Studies |
|---|---|
| 2021 | 2 |
| 2022 | 1 |
| 2023 | 1 |
| 2024 | 1 |
| 2025 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 5 · Other 1
Clarity Pharmaceuticals Ltd (5) · St Vincent's Hospital, Sydney (1)
Often tested with
Tested in the same studies.
Copper Cu 67 Abefolastat Tesaroxetan (1)
Related medicines
As reviewed, each with the page that says it.
- One of Radiopharmaceuticals source
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 1, 1 in phase 3
Studies that test abefolastat tesaroxetan CU-64, phase 3 first.
- Dec 202664Cu-SAR-bisPSMA Positron Emission Tomography: A Phase 3 Study of Participants With Biochemical Recurrence of Prostate CancerPhase 3 · Clarity Pharmaceuticals Ltd
Studies
Open first, then newest update. How each study uses abefolastat tesaroxetan CU-64 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 6
- Positron Emission Tomography Using 64Cu-SAR-bisPSMA in Participants With High-risk Prostate Cancer Prior to Radical ProstatectomyRecruitingPhase 3Clarity Pharmaceuticals LtdNCT06056830Written as 64Cu-SAR-bisPSMA
- 64Cu-SAR-bisPSMA and 67Cu-SAR-bisPSMA for Identification and Treatment of PSMA-expressing Metastatic Castrate Resistant Prostate Cancer (SECuRE)RecruitingPhase 1/2Clarity Pharmaceuticals LtdNCT04868604Written as 64Cu-SAR-bisPSMA
- Comparative Performance of 64Copper [64Cu]-SAR-bis-PSMA vs 68Ga PSMA-11 PET CT for the Detection of Prostate Cancer Recurrence in the Setting of Biochemical Failure Following Radical ProstatectomyCompletedPhase 2St Vincent's Hospital, SydneyNCT06907641Written as 64Cu-SAR-bisPSMA
- 64Cu-SAR-bisPSMA Positron Emission Tomography: A Phase 3 Study of Participants With Biochemical Recurrence of Prostate CancerActive, not recruitingPhase 3Clarity Pharmaceuticals LtdNCT06970847Written as 64Cu-SAR-bisPSMA
- 64Cu-SAR-bisPSMA for Identification of Participants With Recurrence of Prostate Cancer (COBRA)CompletedPhase 1/2Clarity Pharmaceuticals LtdNCT05249127Written as 64Cu-SAR-bisPSMA
- Positron Emission Tomography (PET) Imaging of Participants With Confirmed Prostate Cancer Using 64Cu-SAR-bisPSMA (PROPELLER)CompletedPhase 1Clarity Pharmaceuticals LtdNCT04839367Written as 64Cu-SAR-bisPSMA
Codes
What other systems call abefolastat tesaroxetan CU-64 · ClinicalTrials.gg INT017191
- UNII (FDA) LK5NC9CE4CABEFOLASTAT TESAROXETAN CU-64One source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | LK5NC9CE4C | ABEFOLASTAT TESAROXETAN CU-64 | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.